Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status.

Neuroepidemiology - 1 Jan 2007

Rockwood Kenneth, Howlett Susan, Fisk John, Darvesh Sultan, Tuokko Holly, Hogan David B, Wolfson Christina, McDowell Ian

Abstract excerpt

Lipid-lowering agents (LLAs) might lower the risk of dementia, but any impact on other forms of cognitive impairment is not clear. We examined LLAs in relation to cognitive impairment, no dementia (CIND) and apolipoprotein E4 status. In a case control study from the Canadian Study of Health and Aging, cases (n = 347) had developed CIND between the first and second study waves and controls (n = 693) had no...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Canada
Share to Geriatric Assessment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipidemias

Share to Hypolipidemic Agents

Share to Longitudinal Studies

Share to Memory Disorders

Share to Mental Status Schedule

Source

Identifiers

PMID: 18043005
DOI: 10.1159/000111583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status.PMID 18043005Read ↗

Association of statin use with cognitive decline in elderly African Americans.Semantic proximity Read ↗

Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.Semantic proximity Read ↗

Association of blood lipids, atherosclerosis and statin use with dementia after strokeSemantic proximity Read ↗

Associations of dietary cholesterol and fat, blood lipids, and risk for dementia in older women vary by APOE genotype.Semantic proximity Read ↗

APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.Semantic proximity Read ↗

Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review.Semantic proximity Read ↗

Lipid metabolism in cognitive decline and dementia.Semantic proximity Read ↗

Apolipoprotein E and Its Association With Cognitive Change and Modification of Treatment Effects of Vitamin D3 and Omega-3s on Cognitive Change: Results From the In-Clinic Subset of a Randomized Clinical Trial.Semantic proximity Read ↗

Association of statins use and genetic susceptibility with incidence of Alzheimer's diseaseSemantic proximity Read ↗

Statin use moderates APOE's and CRP's associations with dementia and is associated with lesser dementia severity in ε4 carriers.Semantic proximity Read ↗

APOE e4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset.Semantic proximity Read ↗

Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.